ArticleGastroenterology2018
Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Open access · bronzeAbstract read
In one paragraph
Article in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel Diseases.United European gastroenterology journal · 2025Pooled it
- The Commensal Microbiota and Viral Infection: A Comprehensive Review.Frontiers in immunology · 2019Pooled it
- Characterization of the intrahepatic microbiome in patients with HBV-related end-stage liver disease.Virulence · 2026Article
- Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease.Experimental & molecular medicine · 2026Review
- The gut-liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system.Acta pharmaceutica Sinica. B · 2026Review
- Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast niches.Science advances · 2026Article
- Translocation of bacteria from the gut to the brain in mice.PLoS biology · 2026Article
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- Conserved Ductular Reaction Mechanisms in Biliary Atresia and Primary Sclerosing Cholangitis Derived From Single-Cell and Spatial Transcriptomics.Cellular and molecular gastroenterology and hepatology · 2026Review
- Article
- Microbial Modulation of the Gut-Liver Axis in Autoimmune Liver Diseases.Seminars in liver disease · 2025Review
- The pulmonary commensal Lactobacillus regulated lung γδ T cells to enhance resistance against bacterial infections.Microbiome · 2025Article
- Autoimmune Hepatitis Associated with Other Autoimmune Diseases: A Critical Review.Journal of clinical and translational hepatology · 2025Review
- Liver immunology: Biological role and clinical significance.World journal of hepatology · 2025Review
- Hyperfunctional T cell responses unchecked by regulatory T cells are unable to resolve hepaciviral infection without humoral contribution.Journal of hepatology · 2025Article
- Article
- Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study.BMJ open gastroenterology · 2025Article
- Gut microbiome and liver diseases.Fundamental research · 2025Review
- Gut-X axis.iMeta · 2025Review
- Changes in gut microbiota of gallstone mice at different altitudes based on 16S rDNA sequencing.Frontiers in microbiomes · 2025Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 2 institutions in 1 country.
Dana TedescoEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia.
Manoj ThapaEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia.
Chui Yoke ChinDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Emory Antibiotic Resistance Center, Atlanta, Georgia.
Yong GeDepartment of Infectious Disease and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida.
Minghao GongDepartment of Infectious Disease and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida.
Jing LiDepartment of Infectious Disease and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida.
Sanjeev GumberDivision of Pathology and Laboratory Medicine, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia.
Patrick SpeckEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia.
Elizabeth J ElrodEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia.
Eileen M BurdDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Emory Antibiotic Resistance Center, Atlanta, Georgia; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
William H KitchensDepartment of Surgery, Transplant, Emory University School of Medicine, Atlanta, Georgia.
Joseph F MaglioccaDepartment of Surgery, Transplant, Emory University School of Medicine, Atlanta, Georgia.
Andrew B AdamsDepartment of Surgery, Transplant, Emory University School of Medicine, Atlanta, Georgia.
David S WeissEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Emory Antibiotic Resistance Center, Atlanta, Georgia.
Mansour MohamadzadehDepartment of Infectious Disease and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida; Division of Hepatology, Gastroenterology, and Nutrition; University of Florida, Gainesville, Florida.
Arash GrakouiEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. Electronic address: arash.grakoui@emory.edu.
Emory University · USUniversity of Florida · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MYNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0MMechanisms of hepatitis C virus persistenceR01AI070101 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH · 2006 to 2016
$3.9MDynamics of antigen specific B and Tfh responses during acute and chronic HCVR01AI136533 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH · 2018 to 2022
$3.8MT cell Immunity and the Outcome of Acute HCV InfectionR01AI126890 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GRAKOUI, ARASH, WALKER, CHRISTOPHER M. · 2016 to 2020
$3.7MT cell compartmentalization and antiviral responseR01AI124680 · NIAID · EMORY UNIVERSITY · PI GRAKOUI, ARASH, ZHU, CHENG · 2016 to 2020
$3.2MMyD88-dependent B cell dysfunction and autoimmunity during chronic liver diseaseK01DK109025 · NIDDK · EMORY UNIVERSITY · PI THAPA, MANOJ · 2017 to 2021
$505kNCRR NIH HHS P51 RR000165NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI070101NIAID NIH HHS R01 AI124680NIAID NIH HHS R01 AI126890NIAID NIH HHS R01 AI136533NIDDK NIH HHS K01 DK109025NIH HHS P51 OD011132
Abstract
BACKGROUND &
aimsVariants at the ABCB4 or MDR2 locus, which encodes a biliary transport protein, are associated with a spectrum of cholestatic liver diseases. Exacerbation of liver disease has been linked to increased hepatic levels of interleukin (IL) 17, yet the mechanisms of this increase are not understood. We studied mice with disruption of Mdr2 to determine how defects in liver and alteration in the microbiota contribute to production of IL17 by intrahepatic γδ T cells.
methodsWe performed studies with Mdr2
resultsMdr2
conclusionsIn Mdr2
Indexed as
Gastrointestinal MicrobiomeAdultAgedAnimalsATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BBile DuctsCells, CulturedCholangitis, SclerosingCholestasisDisease Models, AnimalEnd Stage Liver DiseaseFemaleHepatitis C, ChronicHumansInterleukin-17ATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BInterleukin-17Receptors, Antigen, T-Cell, gamma-deltaImmune ResponseIntestinal MicrobiotaLiver Disease PathogenesisPSC
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.